2. Signaling Pathways
  3. Stem Cell/Wnt
  4. β-catenin

β-catenin

Beta catenin

β-catenin

Related Products

PDF 0.78 MB

β-catenin is a dual function protein, regulating the coordination of cell–cell adhesion and gene transcription. In humans, the CTNNB1 protein is encoded by the CTNNB1 gene. β-catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway. It is a member of the catenin protein family and homologous to γ-catenin. Mutations and overexpression of β-catenin are associated with many cancers, including hepatocellular carcinoma, colorectal carcinoma, lung cancer,malignant breast tumors, ovarian and endometrial cancer. β-catenin is regulated and destroyed by the beta-catenin destruction complex, and in particular by the adenomatous polyposis coli (APC) protein, encoded by the tumour-suppressing APC gene. Therefore genetic mutation of the APC gene is also strongly linked to cancers, and in particular colorectal cancer resulting from familial adenomatous polyposis (FAP).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P11007
    β-catenin inhibitory peptoid
    		Inhibitor
    β-catenin inhibitory peptoid (compound 13) inhibits the β-catenin:TCF interaction with an IC50 of 5.44 µM. β-catenin inhibitory peptoid inhibits both Wnt (IC50 of 0.105 µM) and androgen receptor (AR)-signaling (IC50 of 1.02 µM) in prostate cancer cell lines. β-catenin inhibitory peptoid markedly diminishes cell proliferation of prostate cancer cell lines.
    β-catenin inhibitory peptoid
  • HY-158210
    Wnt/β-catenin-IN-3
    		Inhibitor
    Wnt/β-catenin-IN-3 (compound 17) is a Wnt/β-catenin inhibitor with low micromolarGI50s against various cancer cells. Wnt/β-catenin-IN-3triggers G2/M cell cycle arrest though activation of p53-p21 pathway as well as intrinsic and extrinsic apoptotic death of colon cancer cells.
    Wnt/β-catenin-IN-3
  • HY-169348
    β-catenin-IN-8
    		Inhibitor
    β-catenin-IN-8 (Compound 25) is a β-catenin inhibitor. β-catenin-IN-8 inhibits β-catenin and c-Myc protein levels, and inhibits Wnt-target genes level (Fgf20 and Sall4). β-catenin-IN-8 has colorectal cancer anticancer activities, and has metabolic stability.
    β-catenin-IN-8
  • HY-156398
    Anti-inflammatory agent 60
    		Inhibitor
    Anti-inflammatory agent 60(compound 21) inhibitsnitric oxide production, with anIC50value of 12.95 μM.Anti-inflammatory agent 60reducesiNOS,phosphorylated p65, andβ-cateninexpression in a concentration-dependent manner.
    Anti-inflammatory agent 60
  • HY-W002112R
    (±)-Nornicotine (Standard)
    		Inhibitor
    (±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia.
    (±)-Nornicotine (Standard)
  • HY-P11597
    Getacatetide
    		Inhibitor
    Getacatetide (CY-101) is a peptide-based Wnt/β-catenin inhibitor, which can be used for the study of solid tumors.
    Getacatetide
  • HY-100760R
    Toxoflavin (Standard)
    		Inhibitor
    Toxoflavin (Standard) is the analytical standard of Toxoflavin. This product is intended for research and analytical applications. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor and antibiotic activity[1][2].
    Toxoflavin (Standard)
  • HY-179378
    XRF-1021
    		Inhibitor
    XRF-1021 is an orally active HIPK2 inhibitor (IC50 = 0.18 μM). XRF-1021 reduces the expression of fibrotic markers in TGF-β1 stimulated NRK-49F and HK-2 cells, including Fibronectin, Collagen I and α-SMA. XRF-1021 blocks TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch signaling. XRF-1021 reduces renal injury and fibrosis in vivo. XRF-1021 can be used for the research of chronic kidney disease.
    XRF-1021
  • HY-B0730R
    Pamidronate disodium pentahydrate (Standard)
    		Inhibitor
    Pamidronate (disodium pentahydrate) (Standard) is the analytical standard of Pamidronate (disodium pentahydrate). This product is intended for research and analytical applications. Pamidronate disodium pentahydrate, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium pentahydrate significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium pentahydrate can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
    Pamidronate disodium pentahydrate (Standard)
  • HY-180124
    CDK8-IN-20
    		Inhibitor
    CDK8-IN-20 (Compound 67j) is a selective, potent and orally active type I CDK8 inhibitor with an IC50 of 70.5 nM. CDK8-IN-20 shows IC50 values of 147.8, 726.9 and 217.4 nM for homologous kinase CDK19, CDK7 and CDK9. CDK8-IN-20 can inhibit the Wnt/β-catenin pathway and downregulate the expression of β-catenin, Cyclin D1, and c-Myc. CDK8-IN-20 can induce ROS production and cause G2/M and S phase arrest. CDK8-IN-20can be used for the research of cancer, such as colon cancer.
    CDK8-IN-20
  • HY-14998
    Halofenate
    		Inhibitor
    Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo.
    Halofenate
  • HY-B1057S1
    Nefopam-d4 hydrochloride
    		Inhibitor
    Nefopam-d4 (hydrochloride) is deuterium labeled Nefopam (hydrochloride). Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo.
    Nefopam-d<sub>4</sub> hydrochloride
  • HY-176057
    S118
    		Inhibitor
    S118 is an orally active sphingosine-1-phosphate receptor 2 (S1P2 receptor) inhibitor. S118 prevents the binding of the S1P2 receptor to dapper1 (Dpr1), reduces the accumulation of β-catenin and blocks the nuclear translocation of the S1P2 receptor, thereby inhibiting inflammation, fibrosis, and epithelial-mesenchymal transition (EMT) and exerting anti-idiopathic pulmonary fibrosis (IPF) activity. S118 is promising for research of idiopathic pulmonary fibrosis.
    S118
  • HY-32736R
    Triptonide (Standard)
    		Inhibitor
    Triptonide (Standard) is the analytical standard of Triptonide. This product is intended for research and analytical applications. Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC50 of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects.
    Triptonide (Standard)
  • HY-181999
    PC8
    		Inhibitor
    PC8 is a selective dual inhibitor of PARP1/CDK6, with an IC50 of 0.126 μM for PARP1 and 0.197 μM for CDK6. PC8 does not alter PARP1 expression, but reduces the expression of its downstream target PAR. PC8 inhibits the canonical Wnt/β-catenin signaling pathway. PC8 induces intracellular ROS accumulation and exacerbates DNA damage. PC8 inhibits the proliferation of triple-negative breast cancer (TNBC) cells. PC8 can be used for the research of triple-negative breast cancer.
    PC8
  • HY-W800535
    Cryptolepine
    		Inhibitor
    Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties. Cryptolepine acts as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, MAPK and an activator of AMPKα1/2. It intercalates into DNA, inhibits topoisomerase II (Top II), disrupts mitochondrial dynamics and induces apoptosis. Cryptolepine also exhibits anti-plasmodial and cholinesterase inhibitory activities. Cryptolepine can be used in research related to tumors (melanoma, hepatocellular carcinoma, mammary adenocarcinoma, etc.), malaria, inflammatory diseases and diabetes, particularly in studies focused on inhibiting tumor growth and anti-plasmodial infection.
    Cryptolepine
  • HY-157126
    Pterostilbene-isothiocyanate
    		Inhibitor
    Pterostilbene-isothiocyanate (PTER-ITC) exhibits potent anticancereffects in vitro. Pterostilbene-isothiocyanate against human osteosarcoma cells by abrogating the β-catenin/TCF-4 interaction.
    Pterostilbene-isothiocyanate
  • HY-183631
    PM54-1
    		Inhibitor
    PM54 is an antitumor agent with activity across multiple cancer types. PM54 acts as a transcription and WNT/β-catenin signaling pathway inhibitor. PM54 suppresses oncogenic transcriptional programs, and key malignant pathways, while inducing DNA double-strand breaks, S-phase cell cycle arrest and apoptosis. PM54 enhances innate immune recognition, remodels the tumor microenvironment. PM54 exhibits antitumor activity as monotherapy or in combination in xenograft models. PM54 is applicable to research on various cancers and advanced solid tumors.
    PM54-1
  • HY-123958
    SB772077B
    		Inhibitor
    SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research.
    SB772077B
  • HY-107528
    FRATtide
    		Inhibitor
    FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and β-catenin. FRATtide inhibits GSK-3 binding to Axin.
    FRATtide
Cat. No. Product Name / Synonyms Application Reactivity